Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2026-04-22 @ 5:25 AM
Study NCT ID:
NCT02070458
Status:
COMPLETED
Last Update Posted:
2018-12-13
First Post:
2014-02-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Sponsor:
Case Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10-08
Start Date Type:
ACTUAL
Primary Completion Date:
2017-03-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-15
Completion Date Type:
ACTUAL
First Submit Date:
2014-02-21
First Submit QC Date:
None
Study First Post Date:
2014-02-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-12-12
Last Update Post Date:
2018-12-13
Last Update Post Date Type:
ACTUAL